NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $19.12 -0.09 (-0.47%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$19.12 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ArriVent BioPharma Stock (NASDAQ:AVBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ArriVent BioPharma alerts:Sign Up Key Stats Today's Range$18.65▼$19.5350-Day Range$16.95▼$23.1152-Week Range$15.47▼$36.37Volume225,185 shsAverage Volume277,979 shsMarket Capitalization$775.70 millionP/E RatioN/ADividend YieldN/APrice Target$39.14Consensus RatingBuy Company Overview ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania. Read More ArriVent BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreAVBP MarketRank™: ArriVent BioPharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 608th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ArriVent BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ArriVent BioPharma is -4.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ArriVent BioPharma is -4.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArriVent BioPharma has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ArriVent BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.25% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 5.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.25% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 5.00%, indicating that investor sentiment is decreasing. News and Social Media3.5 / 5News Sentiment1.32 News SentimentArriVent BioPharma has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.Search Interest7 people have searched for AVBP on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.58% of the stock of ArriVent BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVBP Stock News HeadlinesQ3 Earnings Forecast for AVBP Issued By B. RileyAugust 30 at 2:45 AM | americanbankingnews.comCooperman’s Omega bought Atlas Energy and ArriVent in Q2August 14, 2025 | msn.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 1 at 2:00 AM | Stansberry Research (Ad)ArriVent Biopharma price target lowered to $33 from $40 at CitiAugust 12, 2025 | msn.comPositive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic DevelopmentAugust 11, 2025 | tipranks.comArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | finanznachrichten.deArriVent BioPharma Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comBuy Rating for ArriVent BioPharma: Promising Potential of Lead Candidate and Solid Financial PositionJuly 21, 2025 | tipranks.comSee More Headlines AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $26.64 on January 1st, 2025. Since then, AVBP shares have decreased by 28.2% and is now trading at $19.12. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) released its quarterly earnings data on Monday, August, 11th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.20. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an initial public offering on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share. Who are ArriVent BioPharma's major shareholders? Top institutional shareholders of ArriVent BioPharma include Octagon Capital Advisors LP (4.80%), Geode Capital Management LLC (1.74%), Fund 1 Investments LLC (1.30%) and Squarepoint Ops LLC (0.50%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ArriVent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2025Today8/31/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for ArriVent BioPharma$39.14 High Price Target$45.00 Low Price Target$33.00 Potential Upside/Downside+104.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-55.40% Return on Assets-51.97% Debt Debt-to-Equity RatioN/A Current Ratio12.74 Quick Ratio12.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.65 per share Price / Book2.50Miscellaneous Outstanding Shares40,570,000Free Float33,031,000Market Cap$775.70 million OptionableN/A Beta1.17 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AVBP) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.